- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Marlborough Today
By the People, for the People
Nisa Investment Advisors Reduces Boston Scientific Stake
Institutional investor sells over 18,000 shares of medical device company
Apr. 1, 2026 at 10:34am
Got story updates? Submit your updates here. ›
Nisa Investment Advisors LLC, a major institutional investor, reduced its stake in Boston Scientific Corporation by 4.6% in the fourth quarter, selling 18,182 shares of the medical equipment provider's stock.
Why it matters
Boston Scientific is a leading global medical device company, so changes in major institutional investor holdings can signal shifts in market sentiment around the company and its prospects.
The details
According to a recent SEC filing, Nisa Investment Advisors now owns 372,831 shares of Boston Scientific, valued at $35.5 million at the end of the reporting period. The sale represents a 4.6% reduction in Nisa's position in the company.
- Nisa Investment Advisors made the share sale in the fourth quarter of 2025.
The players
Nisa Investment Advisors LLC
A major institutional investor that manages over $37 billion in assets.
Boston Scientific Corporation
A global medical device company that develops and markets a wide range of products used in less-invasive medical procedures.
The takeaway
This transaction suggests that at least one major institutional investor has become more cautious about Boston Scientific's near-term prospects, though the company remains a leader in the medical device industry. Analysts will be closely watching for any further shifts in institutional ownership of Boston Scientific stock.


